Recent studies revealed that AR-targeted therapy induces transcriptional plasticity of intermediate cells towards the acquisition of NEPC, which is reversible in PTEN-deficient prostate cancer cells49; this evidence implicates a required presence by the intermediate cells to facilitate the transition of AR-high cellular subtypes to neuroendocrine phenotype. This evidence concerns the gene AR and prostate cancer.